doi: 10.1016/j.bmc.2012.04.034 94 JungW
Ringleb 7 , Igor Sibon 8 , Omid Halse 2 , Peter Heuschmann 9 , Roland Veltkamp 2,10 , Christian Enzinger 1 1 Department of Neurology, Medical University of Graz, Graz, Austria, 2 Department of Brain Sciences, Imperial College London, London, United Kingdom, 3 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece, 4 Institute de Biomedicine of Seville, IBiS/Virgen Macarena University Hospital/CSIC/University of Seville, Seville, Spain, 5 Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy, 6 Santa Maria della Misericordia Hospital, Perugia, Italy, 7 Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany, 8 Department of Neurology, CHU Bordeaux, Bordeaux University, Bordeaux, France, 9 Institute for Clinical Epidemiology and Biometry (ICE-B), University of Wrzburg, Wrzburg, Germany, 10 Department of Neurology, Alfried-Krupp Krankenhaus, Essen, Germany Background and Aims: Patients with intracerebral haemorrhage (ICH) and atrial fibrillation are at a high risk of ischemic stroke and recurrent ICH
No current UK marketing authorisation for an emideltide medicine was identified
Distinguishing obstructive azoospermia from NOA is crucial for treatment choices and the success of sperm extraction surgery
Oclumed uses 2% NAC, compared to the 1% found in most standard N-Acetylcarnosine eye drops
